KCNIP2 is a regulatory subunit of Kv4/D (Shal)-type voltage-gated A-type potassium channels that modulates channel density, inactivation kinetics, and recovery from inactivation in a calcium-dependent manner. It facilitates trafficking of KCND2 and KCND3 channels to the cell surface and is required for expression of transient outward potassium currents in cardiac tissue. In atrial fibrillation with heart failure, KCNIP2 expression is dysregulated alongside other ion channel genes following Notch pathway activation in left atrial cardiomyocytes 1. KCNIP2 is implicated in multiple cardiac arrhythmias, dilated cardiomyopathy, and inherited conditions including Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia. Recent evidence suggests KCNIP2 also influences tumorigenesis; its long non-coding RNA (KCNIP2-AS1) is downregulated in breast cancer and correlates with tumor grade and mitotic rate 2. In supraventricular tachycardia, KCNIP2 expression is upregulated via TGF-β/SMAD4 signaling, linking it to ion channel dysregulation in this condition 3. Beyond the heart, KCNIP2-expressing inhibitory interneurons in the spinal dorsal horn regulate cold sensitivity 4, and KCNIP2 DNA methylation associates with autism spectrum disorder risk in both brain and blood tissues 5.